Molecular Characterization of Primary Mucosal Melanoma

Mucosal Melanoma Clinical Trial

— MELMUQ  

Official title:

Molecular Characterization of Primary Mucosal Melanoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03319693
• Other study ID #: PA16108
• Status: Active, not recruiting
• Start date: August 28, 2017
• Est. completion date: April 28, 2021

Study information

• Verified date: December 2019
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Primary mucosal melanomas (MPM) are rarer than cutaneous melanomas, but also more severe. They are usually refractory to conventional approaches, regularly excluded from major therapeutic programs and not sensitive to new targeted therapies orphans. " The identification of therapeutic targets and accessibility to existing, developing or future targeted therapies improves the survival of patients with MPM.

The principal goal is to describe, using a large panel of genes, the prevalence of major mutations in a cohort of MPMs based on the population of a French region.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 65
• Est. completion date: April 28, 2021
• Est. primary completion date: April 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014

Exclusion criteria:

• Cutaneous melanoma

• Uveal melanoma

Related Conditions & MeSH terms

• Melanoma
• Mucosal Melanoma

Intervention

Genetic:
• Somatic Genetic
NGS analysis

Locations

Country	Name	City	State
France	Chu Reims	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The frequency of main mutations identified using the NGS panel	NGS panel	Day 0